InterVene, a Redwood City, CA-based clinical-stage medical device company, raised $13M in Series A funding.
The round was led by Treo Ventures and existing investor RiverVest Venture Partners. In conjunction with this financing, Brad Vale, Treo Ventures founding general partner, has joined InterVene’s Board of Directors.
The company intends to use the funds to further enhance the final development of its Recana catheter system, initiation of clinical cases, regulatory submission, and market clearance in the United States. In addition, proceeds will support preparation for initial commercialization and post-market clinical research.
Led by CEO Jeff Elkins, InterVene develops interventional technology for treatment and prophylaxis of the causes of CVI with a specific interest in deep veins and the more severe, challenging aspects of venous disease. The company designed Recana to recanalize and restore patency in chronically obstructed deep veins and venous stents, particularly when recanalization capabilities are limited or when long-term chronic stent maintenance is necessary. Utilizing standard Fluoroscopy/IVUS guided interventional techniques, Recana can be incorporated by vascular specialists already performing deep vein thrombosis (DVT) treatment and deep venous stenting.
The company was formed with assistance from the Stanford Biodesign Fellowship program and was a former Company-In-Residence at the Fogarty Institute for Innovation. It is staffed by interventional cardiovascular professionals and advised by accomplished venous thought-leading physicians.
FinSMEs
08/10/2024